NDA 219921 · Avyxa Holdings
Kyxata
Carboplatin · Intravenous · Platinum-based Drug
Last checked: Nov 20, 2026Latest source record: Aug 8, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Aug 8, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4,077
917 Phase 3, 732 recruiting
FAERS reports
130,077
124,012 serious, 20,461 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS Serious and life-threatening hypersensitivity reactions, including anaphylaxis, can occur with KYXATA within minutes of administration during any cycle. Immediately discontinue KYXATA for severe hypersensitivity reactions and administer appropriate treatment for management of the hypersensitivity reaction [see Warnings and Precautions (5.1) ]. WARNING: HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS Serious and life-threatening hypersensitivity reactions, including anaphylaxis, can occur with KYXATA within minutes of administration during any cycle. ( 5.1 ) Immediately withhold KYXATA for severe hypersensitivity reactions and administer appropriate treatment for management of the hypersensitivity reaction. ( 5.1 )
What it is approved for
From the label in effect Nov 9, 2026.
KYXATA is a platinum-based drug indicated in adults: As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma. ( 1.1 ) As a single-agent for the treatment of ovarian carcinoma recurrent after prior chemotherapy. ( 1.2 ) 1.1 Initial Treatment of Advanced Ovarian Carcinoma KYXATA, as part of a combination regimen, is indicated for the initial treatment of adults with advanced ovarian carcinoma. 1.2 Recurrent Advanced Ovarian Carcinoma KYXATA is indicated for treatment of adults with ovarian carcinoma recurrent after prior chemotherapy.
Mechanism: Carboplatin is a platinum-based drug that binds to DNA and forms DNA cross-links. These crosslinks inhibit DNA replication and transcription and trigger cytotoxic processes that lead to cell death.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- KYXATA · CARBOPLATIN 500MG/50ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- KYXATA · CARBOPLATIN 20MG/2ML (10MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
- KYXATA · CARBOPLATIN 80MG/8ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Carboplatin" as an intervention, any sponsor and status, largest first.
- ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00490139 · 8,381 participants · Start May 16, 2007 · Primary completion Dec 6, 2013
Drug: Lapatinib; Trastuzumab · For: Neoplasms, Breast
Sites: Mobile, Alabama; Anchorage, Alaska; Tucson, Arizona · 924 sites in all
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01358877 · 4,804 participants · Start Nov 8, 2011 · Primary completion Dec 19, 2016
Drug: 5-Fluorouracil; Carboplatin and 8 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Everett, California; Greenbrae, California · 546 sites in all
- Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal CancerPivotal-lookingCompleted
Gynecologic Oncology GroupResearch network
NCT00011986 · 4,312 participants · Start Jan 2001 · Primary completion Mar 2010
Drug: Paclitaxel; Carboplatin and 3 more · For: Primary Peritoneal Carcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer
Sites: Philadelphia, Pennsylvania
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
- BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabPivotal-lookingTerminated
NSABP Foundation IncResearch network
NCT00625898 · 3,509 participants · Start Apr 2008 · Primary completion Jun 2013
Drug: Docetaxel; Trastuzumab and 5 more · For: Breast Cancer
Sites: Birmingham, Alabama; Decatur, Alabama; Huntsville, Alabama · 649 sites in all
Societe Internationale d'Oncologie PediatriqueAcademic, hospital or other
NCT00276640 · 3,417 participants · Start Apr 1, 2004 · Primary completion Dec 31, 2015
Drug: vincristine, carboplatin; vincristine, carboplatin, etoposide · For: Primary Central Nervous System Neoplasms
Sites: Vienna, Austria; Ghent, Belgium; Zagreb, Croatia · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use8,814
- neutropenia7,633
- anaemia7,391
- nausea7,205
- febrile neutropenia6,742
- diarrhoea6,425
- malignant neoplasm progression6,347
- disease progression6,172
- thrombocytopenia6,085
- dyspnoea5,535
- vomiting5,279
- pyrexia4,983
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,263 |
| 2005 | 1,451 |
| 2006 | 1,358 |
| 2007 | 1,482 |
| 2008 | 1,356 |
| 2009 | 1,645 |
| 2010 | 1,876 |
| 2011 | 2,493 |
| 2012 | 3,407 |
| 2013 | 2,798 |
| 2014 | 2,638 |
| 2015 | 3,759 |
| 2016 | 4,289 |
| 2017 | 5,629 |
| 2018 | 7,631 |
| 2019 | 7,570 |
| 2020 | 7,832 |
| 2021 | 9,234 |
| 2022 | 11,523 |
| 2023 | 12,551 |
| 2024 | 13,571 |
| 2025 | 14,133 |
| 2026 | 10,587 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 16, 2026
Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50).
Current · updated Nov 16, 2026
Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, et al. · J Clin Oncol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
Powell MA, Bjørge L, Willmott L, et al. · Ann Oncol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Mok TS, Wu YL, Thongprasert S, et al. · N Engl J Med 2009 · Clinical Trial, Phase III, Comparative Study
- Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.
Rao S, Samalin-Scalzi E, Evesque L, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
Cortes J, Haiderali A, Huang M, et al. · BMC Cancer 2023 · Systematic Review, Network Meta-Analysis
- Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, et al. · Lancet Oncol 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Avyxa Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.